Mary Elizabeth Charlton

Mary Elizabeth Charlton

Auto-generated profile, based on publicly available information

Mary Elizabeth Charlton

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2014 in Cancer
Verified
Journal Article
Open access
PDF file
MCMary E. Charlton
Mary E. Charlton
MAMargaret (Peggy) Adamo
Margaret (Peggy) Adamo
LSLeon Sun
Leon Sun
SDSundeep Deorah
Sundeep Deorah
BACKGROUND: Several changes were made to bladder cancer staging guidelines between the 6th and 7th editions of the American Joint Committee on Cancer (AJCC) Staging Manual. Also, Collaborative Stage (CS) Data Collection System version 2 (CSv2) implemented for 2010 Surveillance, Epidemiology, and End Results (SEER) cases involved collection of 3 new site‐specific factors (SSFs): World Health Organization/International Society of Urological pathology grade (SSF1), size of metastasis in regional lymph nodes (SSF2), and extranodal extension (SSF3). Our objective was to evaluate these new SSFs to assist researchers in their use/interpretation and to describe data quality issues to be addressed moving forward.METHODS: Staging trends were assessed for invasive and noninvasive bladder cancer cases from 2004 to 2010. Among 2010 cases, staging was compared using the AJCC 6th and 7th edition guidelines, and evaluation of completeness/quality of the SSFs was performed in relevant subgroups.RESULTS: Age‐adjusted incidence rates and proportions of cases by stage remained steady from 2004 to 2010. Changes from the AJCC 6th to 7th editions caused no substantial movement between stages. SSF1 had a known value in 82% of cases, which was higher than the traditional SEER grade/differentiation variable. SSF2 and SSF3 were less complete, with 41% and 37% having known values, respectively, among cases with lymph node involvement (according to CS lymph node variable).CONCLUSIONS: SSF1 was more complete and straightforward to interpret than the traditional grade/differentiation variable. SSF2 and SSF3 were less complete, may be associated with data quality issues, and should only be used among cases with known lymph node involvement Cancer 2014;120(23 suppl):3815‐25. © 2014 American Cancer Society.

9 December 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MCMary E. Charlton
Mary E. Charlton
AKAmanda R. Kahl
Amanda R. Kahl
AGAlissa A. Greenbaum
Alissa A. Greenbaum
JKJordan J. Karlitz
Jordan J. Karlitz
CLChi Lin
Chi Lin
VCVivien W. Chen
Vivien W. Chen
Purpose: KRAS mutations and tumor location have been associated with response to targeted therapy among patients with stage IV colorectal cancer (CRC) in various trials. This study performed the first population-based examination of associations between KRAS mutations, tumor location, and survival, and assessed factors associated with documented KRAS testing. Methods: Patients with stage IV adenocarcinoma of the colon/rectum diagnosed from 2010 to 2013 were extracted from SEER data. Analyses of patient characteristics, KRAS testing, and tumor location were conducted using logistic regression. Cox proportional hazards models assessed relationships between KRAS mutations, tumor location, and risk of all-cause death. Results: Of 22,542 patients, 30% received KRAS testing, and 44% of these had mutations. Those tested tended to be younger, married, and metropolitan area residents, and have private insurance or Medicare. Rates of KRAS testing also varied by registry (range, 20%–46%). Patients with right-sided colon cancer (vs left-sided) tended to be older, female, and black; have mucinous, KRAS-mutant tumors; and have a greater risk of death (hazard ratio [HR], 1.27; 95% CI, 1.22–1.32). KRAS mutations were not associated with greater risk of death in the overall population; however, they were associated with greater risk of death among patients with left-sided colon cancer (HR, 1.19; 95% CI, 1.05–1.33). Conclusions: This large population-based study showed that among patients initially diagnosed with stage IV CRC, right-sided colon cancer was associated with greater risk of death compared with left-sided cancer, and KRAS mutations were only associated with risk of death in left-sided colon cancer. An unexpected finding was that among patients with stage IV disease, right-sided cancer was more commonly seen in black patients versus whites. Future studies should further explore these associations and determine the role of biology versus treatment differences. In addition, use of KRAS testing is increasing, but there is wide geographic variation wherein disparities related to insurance coverage and rurality may warrant further study.

24 April 2022 in The Journal of Rural Health
Verified
Journal Article
Closed access
BGBreanna B. Greteman
Breanna B. Greteman
CGCrystal J. Garcia‐Auguste
Crystal J. Garcia‐Auguste
BGBrian M. Gryzlak
Brian M. Gryzlak
AKAmanda R. Kahl
Amanda R. Kahl
SLSusan K. Lutgendorf
Susan K. Lutgendorf
MCMary E. Charlton
Mary E. Charlton

1 December 2014 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
SSSteven M. Sperry
Steven M. Sperry
MCMary E. Charlton
Mary E. Charlton
NPNitin A. Pagedar
Nitin A. Pagedar
There were an estimated 68 000 new melanoma cases in the United States in 2010, and the incidence seems to be increasing.1 At diagnosis, 82% of patients have localized disease, while in 11% disease has already spread to regional sites.2 Any regional lymph node metastasis in melanoma decreases survival.3 Sentinel lymph node biopsy (SLNB) for melanoma was introduced in the early 1990s to identify the presence of occult regional metastatic disease.4 The procedure has been shown to provide important prognostic information3,5 and obviates the need for elective regional node dissection in most patients.6 Patients with a positive result from an SLNB may be offered more aggressive treatment, including regional node dissection, other adjuvant therapy, or enrollment in clinical trials. Quiz Ref ID Although SLNB identifies patients with microscopic nodal disease, improves regional disease control,7 and may facilitate the escalation of treatment, it is still controversial whether there is any therapeutic benefit of the procedure, especially in terms of survival.8-10 In fact, the only randomized clinical (RCT) to evaluate the question of a survival benefit demonstrated no difference in disease-specific survival (DSS) for those treated with an SLNB for intermediate-thickness melanoma.11,12 A criticism of the trial has been that it was underpowered to detect a small but clinically significant survival effect.13

1 June 2015 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
AWAlan N. West
Alan N. West
MCMary E. Charlton
Mary E. Charlton
MVMary Vaughan-Sarrazin
Mary Vaughan-Sarrazin
Veterans who are hospitalized in both VA and non-VA hospitals within a short timespan may be at risk for fragmented or conflicting care. To determine the characteristics of these “dual users,” we analyzed administrative hospital discharge data for VA-enrolled veterans of any age in seven states, including any VA or non-VA hospitalizations they had in 2004–2007. For VA enrollees in Arizona, Iowa, Louisiana, Florida, South Carolina, Pennsylvania, or New York in 2007, we merged 2004–2007 discharge data for all VA hospitalizations and all non-VA hospitalizations listed in state health department or hospital association databases. For patients hospitalized in 2007, we compared those younger or older than 65 years who had one or multiple hospitalizations during the year, split into users of VA hospitals, non-VA hospitals, or both (“dual users”), on demographics, priority for VA care, travel times, principal diagnoses, co-morbidities, lengths of stay, and prior (2004–2006) hospitalizations, using chi-square analysis or ANOVA. Multiply hospitalized patients were compared with multinomial logistic regressions to predict non-VA and dual use. Payers for non-VA hospitalizations also were compared across groups. Of unique inpatients in 2007, 38 % of those 65 or older were hospitalized more than once during the year, as were 32 % of younger patients; 3 and 8 %, respectively, were dual users. Dual users averaged the most index-year (3.7) and prior (1.5) hospitalizations, split evenly between VA and non-VA. They also had higher rates of admission for circulatory diseases, symptoms/signs/ill-defined conditions, and injury and poisoning, and more admissions for multiple diagnostic categories; among younger patients they had the highest rate of mental disorders admissions. Higher income, non-rural residence, greater time to VA care, lower VA priority, prior non-VA hospitalization, no prior VA hospitalization, and several medical categories predicted greater non-VA use. Among younger patients, however, mental disorders predicted more dual use but less exclusively non-VA use. Dual users’ non-VA admissions were more likely than others’ to be covered by payers other than Medicare or commercial insurance. Younger dual users require more medical and psychiatric treatment, and rely more on government funding sources. Effective care coordination for these inpatients might improve outcomes while reducing taxpayer burden.

1 May 2016 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
MCMary E. Charlton
Mary E. Charlton
JHJennifer E. Hrabe
Jennifer E. Hrabe
KWKara B. Wright
Kara B. Wright
JSJennifer A. Schlichting
Jennifer A. Schlichting
BMBradley D. McDowell
Bradley D. McDowell
JCJohn W. Cromwell
John W. Cromwell